Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 427.4 g/mol |
---|---|
Molecular Formula | C20H21N5O6 |
XLogP3 | 0.2 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 9 |
Exact Mass | 427.14918341 g/mol |
Monoisotopic Mass | 427.14918341 g/mol |
Topological Polar Surface Area | 187 A^2 |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 748 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Alimta |
PubMed Health | Pemetrexed (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Pemetrexed disodium heptahydrate has the chemical name L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate. It is a white to almost-white solid with a molecular formula of C... |
Active Ingredient | Pemetrexed; Pemetrexed disodium |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | eq 500mg base/vial; 500mg; eq 100mg base/vial |
Market Status | Prescription |
Company | Lilly |
2 of 2 | |
---|---|
Drug Name | Alimta |
PubMed Health | Pemetrexed (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Pemetrexed disodium heptahydrate has the chemical name L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate. It is a white to almost-white solid with a molecular formula of C... |
Active Ingredient | Pemetrexed; Pemetrexed disodium |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | eq 500mg base/vial; 500mg; eq 100mg base/vial |
Market Status | Prescription |
Company | Lilly |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21180
Submission : 2008-01-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31215
Submission : 2016-11-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-03-17
Pay. Date : 2014-11-25
DMF Number : 28758
Submission : 2014-12-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29821
Submission : 2015-09-25
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Reply
24 May 2023
Reply
01 Sep 2021
Reply
02 Jul 2020
Reply
25 Jan 2020
Reply
18 Feb 2019
Reply
28 Jan 2019
Reply
29 Sep 2021
Reply
06 Jul 2021
Reply
12 Jun 2021
Reply
17 May 2021
Reply
03 Mar 2021
Reply
04 Jan 2021
Reply
16 Nov 2020
Reply
20 Nov 2018
Reply
18 Mar 2019
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-10-28
US Patent Number : 9604990
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 209472
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-10-28
Patent Expiration Date : 2036-02-19
US Patent Number : 11793813
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209472
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-02-19
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A ALIMTA manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ALIMTA, including repackagers and relabelers. The FDA regulates ALIMTA manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ALIMTA API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ALIMTA manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ALIMTA supplier is an individual or a company that provides ALIMTA active pharmaceutical ingredient (API) or ALIMTA finished formulations upon request. The ALIMTA suppliers may include ALIMTA API manufacturers, exporters, distributors and traders.
click here to find a list of ALIMTA suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ALIMTA DMF (Drug Master File) is a document detailing the whole manufacturing process of ALIMTA active pharmaceutical ingredient (API) in detail. Different forms of ALIMTA DMFs exist exist since differing nations have different regulations, such as ALIMTA USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ALIMTA DMF submitted to regulatory agencies in the US is known as a USDMF. ALIMTA USDMF includes data on ALIMTA's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ALIMTA USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ALIMTA suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ALIMTA as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ALIMTA API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ALIMTA as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ALIMTA and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ALIMTA NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ALIMTA suppliers with NDC on PharmaCompass.
ALIMTA Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ALIMTA GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ALIMTA GMP manufacturer or ALIMTA GMP API supplier for your needs.
A ALIMTA CoA (Certificate of Analysis) is a formal document that attests to ALIMTA's compliance with ALIMTA specifications and serves as a tool for batch-level quality control.
ALIMTA CoA mostly includes findings from lab analyses of a specific batch. For each ALIMTA CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ALIMTA may be tested according to a variety of international standards, such as European Pharmacopoeia (ALIMTA EP), ALIMTA JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ALIMTA USP).
LOOKING FOR A SUPPLIER?